Results 141 to 150 of about 9,804 (228)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Drug Design, Development and Therapy, 2019
Thomas G Cotter,1 Donald M Jensen21Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL, USA; 2Section of Hepatology, RUSH University Medical Center, Chicago, IL, USAAbstract: Direct-acting antiviral (DAA) therapy has changed the ...
Cotter TG, Jensen DM
doaj  

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. [PDF]

Antimicrob Agents Chemother, 2015
Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY.   +12 more
europepmc   +1 more source

Linezolid for multidrug-resistant tuberculosis. [PDF]

, 2013
Cox, H, Ford, N, Goemaere, E, Hughes, J
core   +2 more sources

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. [PDF]

Antimicrob Agents Chemother, 2017
Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC.   +8 more
europepmc   +1 more source

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. [PDF]

Antimicrob Agents Chemother, 2016
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W.   +16 more
europepmc   +1 more source

Phospholipid-driven conformational switching of HCV NS5A links protein folding to replication membrane remodeling. [PDF]

Sci Adv
Bulankina AV, Richter RM, Nettles JH, Yamane D, Grimm C, Karami Y, Stanton RA, Introini B, Hermann J, Charif H, König MS, Stroß C, Ortiz C, Kraus N, Wood D, Galceran F, Abele R, Maigret B, Schinazi RF, Zeuzem S, Biondi RM, Yi M, Tampé R, Kudryashev M, Welsch C.   +24 more
europepmc   +1 more source

Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. [PDF]

J Virol
Kennedy MJ, Wolfisberg R, Lundsgaard EA, Thorselius CE, Collignon L, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. [PDF]

Oncotarget, 2018
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Moriyama M, Kato N.   +17 more
europepmc   +1 more source

Generation of a HiBiT-expressing recombinant rat hepacivirus supporting both in vivo and in vitro infection. [PDF]

PLoS Pathog
Akaike Y, Tanaka T, Kasai H, Yamashita A, Matsuura Y, Moriishi K.   +5 more
europepmc   +1 more source

High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. [PDF]

Liver Int, 2016
Poordad F, Landis CS, Asatryan A, Jackson DF, Ng TI, Fu B, Lin CW, Yao B, Kort J.   +8 more
europepmc   +1 more source